Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $68,238.45 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 2,241 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares in the company, valued at $2,438,588.25. This represents a 2.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ellen Chiniara also recently made the following trade(s):

• On Monday, January 6th, Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75.

Kymera Therapeutics Stock Down 3.8 %

Shares of KYMR stock traded down $1.18 during mid-day trading on Monday, reaching $30.17. 982,064 shares of the company’s stock traded hands, compared to its average volume of 578,939. The company’s 50-day moving average price is $38.81 and its 200-day moving average price is $43.66. The company has a market cap of $1.95 billion, a P/E ratio of -12.89 and a beta of 2.18. Kymera Therapeutics, Inc. has a 12 month low of $29.16 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on KYMR shares. UBS Group lowered their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Morgan Stanley increased their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. BMO Capital Markets assumed coverage on Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 target price on the stock. Finally, Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.69.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its stake in Kymera Therapeutics by 3.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company’s stock valued at $276,395,000 after buying an additional 224,859 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after acquiring an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after acquiring an additional 650,000 shares in the last quarter. FMR LLC raised its position in shares of Kymera Therapeutics by 5.8% in the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after purchasing an additional 282,301 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock worth $196,617,000 after purchasing an additional 133,546 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.